A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
← catalyst calendarNCT06792695 · readout in 315 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
80estimated
Sites
76
Countries
Australia, Canada, China +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-12 | actual | When the study began enrolling |
| Primary completion | 2027-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-09-29 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Colorectal Cancer
Interventions
- Drug: Volrustomig — also filed as MEDI5752
- Drug: FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
- Drug: Bevacizumab
Primary outcomes
what the primary-completion date above is the date OFProgression Free Survival (PFS)
measured Approximately 3 years
Number of Participants with Adverse Events (AEs)
measured Approximately 3 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed